NBE-Therapeutics AG
NBE-Therapeutics is a biotech company based in Basel, Switzerland, focused on developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. Acquired by Boehringer Ingelheim in December 2020, the company leverages innovative technologies and collaborates with global partners to advance oncology therapies. Their mission is to transform cancer care with precision medicine and targeted treatments.
Industries
Nr. of Employees
small (1-50)
NBE-Therapeutics AG
Hochbergerstrasse 60I, CH-4057 Basel
Patents
Anthracycline-based antibody drug conjugates having high in vivo tolerability
US-12121527-B2
View Details
Anthracycline-based antibody drug conjugates having high in vivo tolerability
US-12121527-B2
View DetailsProducts
ADC product pipeline based on site-specific conjugation and linker-payload platform
A portfolio of antibody-drug conjugate candidates developed using site-specific conjugation technologies and potent payloads, progressing through preclinical stages toward clinical evaluation.
Anthracycline-derived ADC payload (PNU-type)
A highly potent anthracycline-derived cytotoxic payload designed for ADC use, inducing DNA damage and immunogenic cell death and enabling targeting of low-antigen-density tumors.
ADC product pipeline based on site-specific conjugation and linker-payload platform
A portfolio of antibody-drug conjugate candidates developed using site-specific conjugation technologies and potent payloads, progressing through preclinical stages toward clinical evaluation.
Anthracycline-derived ADC payload (PNU-type)
A highly potent anthracycline-derived cytotoxic payload designed for ADC use, inducing DNA damage and immunogenic cell death and enabling targeting of low-antigen-density tumors.
Services
Discovery and functional screening of full-length antibody libraries on mammalian precursor B cells using transposition-mediated display to identify therapeutic antibodies with favorable manufacturability and ADC suitability.
CMC-validated, GMP-established site-specific conjugation process to produce homogeneous ADCs with precise DAR control and compatibility with multiple payload and linker chemistries.
Preclinical testing in syngeneic tumor models and mechanism-of-action studies to assess anti-tumor efficacy, induction of adaptive immunity, and potential for combination with immune-modulating therapies.
Engagement in collaborative research, licensing and partnering to advance ADC technology and pipeline programs.
Discovery and functional screening of full-length antibody libraries on mammalian precursor B cells using transposition-mediated display to identify therapeutic antibodies with favorable manufacturability and ADC suitability.
CMC-validated, GMP-established site-specific conjugation process to produce homogeneous ADCs with precise DAR control and compatibility with multiple payload and linker chemistries.
Preclinical testing in syngeneic tumor models and mechanism-of-action studies to assess anti-tumor efficacy, induction of adaptive immunity, and potential for combination with immune-modulating therapies.
Engagement in collaborative research, licensing and partnering to advance ADC technology and pipeline programs.
Expertise Areas
- Antibody-drug conjugate (ADC) development
- Site-specific conjugation and DAR control
- Anthracycline-derived payload development
- Mammalian cell-based antibody discovery
Key Technologies
- Sortase-mediated site-specific conjugation
- Transposition-mediated mammalian cell antibody display
- Anthracycline-based DNA-intercalating cytotoxic payloads
- Controlled drug-to-antibody ratio (DAR) generation
News & Updates
NBE-Therapeutics will attend the AACR Annual meeting in Chicago, bringing together cancer research professionals for discussions on recent developments.
NBE-Therapeutics will participate in the ASCO Conference in Chicago, engaging with oncology leaders.
NBE-Therapeutics plans to attend the ESMO Congress in Berlin, a platform for global oncology insights.
NBE-Therapeutics will sponsor Swiss Biotech Day in Basel, a conference for life sciences professionals.
NBE-Therapeutics will attend the AACR Annual meeting in Chicago, bringing together cancer research professionals for discussions on recent developments.
NBE-Therapeutics will participate in the ASCO Conference in Chicago, engaging with oncology leaders.
NBE-Therapeutics plans to attend the ESMO Congress in Berlin, a platform for global oncology insights.
NBE-Therapeutics will sponsor Swiss Biotech Day in Basel, a conference for life sciences professionals.